Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Oncology Institute ( (TOI) ).
On August 8, 2025, Richard Barasch resigned as Chairman of the Board of The Oncology Institute, effective August 12, 2025, with no disagreements cited. Anne McGeorge, with extensive financial and healthcare advisory experience, will succeed him, bringing her strategic guidance to the role. Her appointment is expected to strengthen the company’s leadership and continue its mission of providing exceptional oncology care.
The most recent analyst rating on (TOI) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Oncology Institute stock, see the TOI Stock Forecast page.
Spark’s Take on TOI Stock
According to Spark, TipRanks’ AI Analyst, TOI is a Neutral.
The Oncology Institute’s overall score is mainly impacted by its weak financial performance, characterized by negative margins and cash flow issues. Despite positive technical indicators and strategic growth initiatives highlighted in the earnings call, the company’s valuation remains a concern due to its negative P/E ratio. The potential for future profitability is acknowledged but contingent upon operational improvements.
To see Spark’s full report on TOI stock, click here.
More about Oncology Institute
Founded in 2007, The Oncology Institute, Inc. (NASDAQ: TOI) is a leading provider of value-based oncology care in the United States, offering specialized cancer treatment to approximately 1.9 million patients. The company operates over 100 clinics and affiliate locations across five states, providing services such as clinical trials and transfusions.
Average Trading Volume: 2,166,874
Technical Sentiment Signal: Buy
Current Market Cap: $377.8M
For detailed information about TOI stock, go to TipRanks’ Stock Analysis page.